Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
A director at Bard(C.R.) Inc sold 1,100 shares at 335.280USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Becton Dickinson continues to move closer to completing its acquisition of C.R. Bard, which we expect to take place soon. While the Federal Trade Commission, or FTC, has yet to press Becton to divest any products for antitrust reasons, the firm has reached agreement with Europe's competition enforcer to divest its core biopsy needle business, as well as a tissue marker product in the pipeline. This was a product line that was part of Carefusion's legacy business, which was purchased by Becton in...
MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYSE: BCR) today reported 2017 third quarter financial results. The company has included supplemental financial data on its website related to this earnings release. Third quarter 2017 net sales were $989.8 million, an increase of 5 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, third quarter 2017 net sales also increased 5 percent over the prior-year period. During the third quarter of 2017, the company experienced t...
Becton Dickinson continues to move closer to completing its acquisition of CR Bard. The boards of both firms have voted unanimously to approve the deal, and we don’t expect much in terms of antitrust objections because there’s little overlap in the product portfolios. We anticipate the deal to close in the fall....
MURRAY HILL, N.J.--(BUSINESS WIRE)-- The Board of Directors of C. R. Bard, Inc. (NYSE-BCR) today declared a regular quarterly dividend of 26 cents per share on Bard's common stock. In connection with the pending merger with Becton, Dickinson & Company, the quarterly dividend will be payable on December 29, 2017 to shareholders of record at the close of business on December 8, 2017. C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative...
C R BARD INCO. (US), a company active in the Medical Equipment industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date September 8, 2017, the closing price...
MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYSE:BCR) today announced the LUTONIX® 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) for a new indication and is now available for sale in the United States. With this approval, the LUTONIX® 035 DCB Catheter becomes the first and only drug coated balloon that is FDA approved as safe and effective in end stage renal disease (ESRD) patients with stenotic lesions in dialysis arteriovenous (AV) fistu...
Becton Dickinson continues to move closer to completing its acquisition of CR Bard. The boards of both firms have voted unanimously to approve the deal, and we don’t expect much in terms of antitrust objections because there’s little overlap in the product portfolios. We anticipate the deal to close in the fall....
MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYSE:BCR) today reported 2017 second quarter financial results. Second quarter 2017 net sales were $979.7 million, an increase of 5 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, second quarter 2017 net sales increased 6 percent over the prior-year period. For the second quarter 2017, net sales in the U.S. were $660.2 million, an increase of 4 percent over the prior-year period. Net sales outside the U.S. were $319.5 ...
MURRAY HILL, N.J.--(BUSINESS WIRE)-- The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today declared a regular quarterly dividend of 26 cents per share on Bard's common stock. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on August 4, 2017 to shareholders of record at the close of business on July 24, 2017. C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased C. R. Bard, Inc. (NYSE: BCR) stock prior to April 23, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of C. R. Bard, Inc. to Beckton, Dickinson and Company ("BD") (NYSE: BDX). Under the terms of transaction, C. R. Bard shareholders will receive $222.93 in cash and 0.5077 of a BD share for each share of C. R. ...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of C.R. Bard, Inc. (NYSE: BCR) (“BCR” or the “Company”) relating to the proposed buyout of BCR by Becton, Dickinson and Company. Under the terms of the agreement, BCR shareholders are anticipated to receive $222.93 in cash and 0.5077 shares of Becton, Dickinson stock for each share of...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of C.R. Bard, Inc. (NYSE: BCR) (“BCR” or the “Company”) relating to the proposed buyout of BCR by Becton, Dickinson and Company. Under the terms of the agreement, BCR shareholders are anticipated to receive $222.93 in cash and 0.5077 shares of Becton, Dickinson stock for each share of...
With the announcement of Becton Dickinson’s agreement to purchase CR Bard, we plan to raise our fair value estimate to $317 per share, reflecting BD’s offer price. We think CR Bard shareholders are getting a pretty premium, at roughly 61% more than our intrinsic value. At this point, we do not expect any substantive antitrust issues to derail this deal. We’ve long been fans of Bard’s strategy, which is focused on consumable products for hospitals that contribute to greater safety, bett...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of C.R. Bard, Inc. (NYSE: BCR)? Did you purchase any of your shares prior to April 24, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of C.R. Bard, Inc. (“Bard” or the “Company”) (NYSE: BCR) regarding possible breaches o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.